간편하게 보는 뉴스는 유니콘뉴스
LC-Plasma-based Vaccine Research Selected for SCARDA Project

· 등록일 May. 09, 2024 15:40

· 업데이트일 2024-05-10 00:00:20

TOKYO--(Business Wire / Korea Newswire)--Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and National Institute of Infectious Diseases (NIID) are jointly conducting studies to investigate the protective efficacy of L. lactis strain Plasma [postbiotic] (LC-Plasma) immunization against infectious diseases. We now announce that a proposal for our collaborative research has currently been accepted as a project for research and development into new modalities contributing to vaccine development by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) in the Japan Agency for Medical Research and Development (AMED).

· Information on the Research Project
Title: Development of an intranasal Lactococcus lactis strain Plasma vaccine inducing innate memory
Representative: Tetsuro Matano, Deputy Director-General, NIID
Representative: Daisuke Fujiwara, Executive Officer, General Manager, Health Science Institute, Kirin Holdings

· Unique point
This research aims at developing an intranasal LC-Plasma vaccine to induce innate immunity for prevention of respiratory virus infection.

Backgrounds
SCARDA was established at AMED in March, 2022, based on the national strategy, to strengthen strategic research funding and to promote the formation of world-class research and development centers (https://www.amed.go.jp/en/program/list/21/index.html). SCARDA is supporting Research & Development for new generation vaccines. Traditional vaccines are expected to induce adaptive immune responses including antibody and T cell responses to prevent infection with pathogens such as viruses and bacteria. Recently, the concept of trained immunity has been discussed and there have been several attempts to develop vaccines inducing effective innate responses against infectious diseases, which has not yet been achieved.

LC-Plasma is characterized by its ability to activate plasmacytoid dendritic cells (pDCs) and stimulate interferon production, leading to enhancement of innate immune responses. Through joint research with NIID, Kirin Holdings has confirmed that SARS-CoV-2 replication is inhibited by the culture supernatants of pDCs stimulated with LC-Plasma (Ishii et al, BBRC 662:26, 2023).

Kirin Holdings and NIID are now conducting collaborative research for the development of vaccines inducing innate immune responses against respiratory virus infection by utilizing LC-Plasma for medical use. This project is to explore the potential of intranasal LC-Plasma vaccination to prevent respiratory infection with viruses including SARS-CoV-2 and influenza viruses.

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals. Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

* Creating Shared Value. Combined added value for consumers as well as for society at large.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507111790/en/

Website: https://www.kirinholdings.com/en/ View Korean version of this release Contact Kirin Holdings Company, Limited
Corporate Communication Department
+81-3-6837-7028
[email protected]

National Institute of Infectious Diseases
+81-3-5285-1111
[email protected]
This news is a press release provided by Kirin Holdings Company, Limited. Korea Newswire follows these editorial guidelines. Kirin Holdings Company, Limited News ReleasesSubscribeRSS LC-플라즈마 기반 백신 연구, SCARDA 프로젝트에 선정 기린 홀딩스(Kirin Holdings Company, Limited)(도쿄증권거래소: 2503)와 국립감염병연구소(National Institute of Infectious Diseases, NIID)가 L. 락티스(L. lactis) 균주 플라즈마 [포스트바이오틱](LC-플라즈마) 면역의 감염병 예방 효과를 조사하는 공동 연구를 진행하고 있다. 이 공동 연구에 대한 제... 5월 9일 15:40 Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28! Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday). This product is a collaboration between Kirin iMUSE, Japan’s first*1 immune care brand, and Kao Healthya, Japa... 2023년 11월 28일 13:20 ... More  More News Health Infection Control Life Style Food & Beverage Coporate Expansion Overseas Kirin Holdings Co... All News Releases 
인기 기사12.23 14시 기준
서울--(뉴스와이어)--산업통상자원부(장관 안덕근, 이하 산업부)와 KOTRA(사장 유정열)는 중소·중견기업의 수출경쟁력 강화를 위해 2024년 수출바우처 사업(산업 글로벌 진출역량 강화사업) 참여기업 2차 모집을 진행한다. 수출바우처 사업은 2017년부터 시작된 사업으로 연 1회 선정을 기본으로 해 왔으나, 높은 경쟁률 해소와...
서울--(뉴스와이어)--정보보안 소프트웨어 전문기업 휴네시온(코스닥 290270, 대표이사 정동섭)은 2023년 망연계 시장점유율 55%를 기록하며, 2015년부터 9년 연속 망연계 시장 점유율 1위(조달정보개방포털 특정품목 조달내역 기준)를 달성했다고 10일 밝혔다. ...
두바이, 아랍에미리트--(뉴스와이어)--프로캡 인터내셔널(Procap International)은 수개월간의 꼼꼼한 계획과 준비 끝에 6월 6일 ‘LCW UAE Cycle (LCW)’이라는 제목의 첫 번째 공식 마케팅 이벤트를 시작했다. 프로캡 인터내셔널, 첫...
서울--(뉴스와이어)--아스콘 제조기업 에스지이(SG, 코스닥 255220, 대표이사 박창호)가 최근 자사의 친환경 에코스틸아스콘 제조 기술에 대해 공공기관의 기술 등록을 잇달아 완료했다. 에스지이 CI ...
서울--(뉴스와이어)--한국도로교통공단 서울특별시지부(본부장 나재필)가 생활권 주요교차로 개선사업 4개소를 완료했다. 종로 흥인지문 교차로의 개선 전 현장 모습 ...
서울--(뉴스와이어)--LG에너지솔루션이 유럽 지역 전기 상용차(버스·트럭 등) 배터리 시장 공략을 가속화한다. LG에너지솔루션 폴란드 브로츠와프 공장 8일 LG에너지솔루션은 폴란드 배터리 팩 제조·판매...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.